---
title: "The innovative drug concept continues to strengthen, Sunshine Guojian Pharmaceutical has achieved 4 consecutive limit-ups"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/241334772.md"
description: "Sunshine Guojian Pharmaceutical achieved a 20CM4 consecutive limit-up, Hicin Pharmaceutical rose over 10%, and Shutai Shen, HISOAR, Ruizhi Pharmaceutical, SHANGHAI YIZHONG, and others had significant gains"
datetime: "2025-05-22T02:16:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/241334772.md)
  - [en](https://longbridge.com/en/news/241334772.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/241334772.md)
generator: "portal-rs"
---

# The innovative drug concept continues to strengthen, Sunshine Guojian Pharmaceutical has achieved 4 consecutive limit-ups

Sunshine Guojian Pharmaceutical has achieved a 20CM four consecutive limit up, Hicin Pharmaceutical has risen over 10%, and Shutai Shen, HISOAR, Ruizhi Pharmaceutical, SHANGHAI YIZHONG, and others have seen significant gains

### Related Stocks

- [688336.CN](https://longbridge.com/en/quote/688336.CN.md)
- [002099.CN](https://longbridge.com/en/quote/002099.CN.md)
- [688091.CN](https://longbridge.com/en/quote/688091.CN.md)
- [300584.CN](https://longbridge.com/en/quote/300584.CN.md)
- [300149.CN](https://longbridge.com/en/quote/300149.CN.md)
- [300204.CN](https://longbridge.com/en/quote/300204.CN.md)

## Related News & Research

- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)
- [Negative Link Announces Global Expansion and Next Phase of Growth](https://longbridge.com/en/news/296644416.md)
- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [CANSINOBIO  Tetanus Vaccine New Drug Application Approved](https://longbridge.com/en/news/296498620.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**